Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sionna Therapeutics, Inc. (SION)
USD43.30
+0.71 (+1.66%)
US NASDAQ Healthcare Biotechnology
Address
21 Hickory Drive Suite 500 2451
Waltham, MA, US
Waltham, MA, US
CEO
Michael Cloonan
Website
sionnatx.com
IPO
2025-02-07
CIK 2036042 ISIN US8294011080
Description
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD43.30
+0.71 (+1.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
429.0K
Beta
1.29
Float Shares
25.77M
Free Float %
57.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.32% | -1.84% | +3.23% | +14.93% | +20.18% | +4.81% | +236.09% | +72.48% | +72.48% | +72.48% | +72.48% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
43.30
Low
24.00
-44.6%
Consensus
46.25
+6.8%
Median
51.50
+19.0%
High
58.00
+34.0%
DCF (Unlevered)
1.23
-97.2%
DCF (Levered)
1.25
-97.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
91% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 9 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
50.00
+15.5%
|
| Last Year | 6 |
42.00
-3.0%
|
| All Time | 7 |
42.43
-2.0%
|
Quality scores
Altman Z-Score
72.32
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-34.3% Q1'26: -60.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-111.8% Q1'26: -147.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-9.4% ★ Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.10× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 EPS Ana. |
Dec 2027 9 Rev. Ana. 6 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
3.33M
3.33M – 3.33M
|
4.29M
4.29M – 4.29M
+28.6% YoY
|
32.60M
32.60M – 32.60M
+660.7% YoY
|
81.41M
81.41M – 81.41M
+149.7% YoY
|
| EBITDA |
-69.89M
|
-88.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-70.56M
|
-88.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-61.69M
est: -232.24M (+73.4%)
|
-75.27M
est: -75.27M (+0.0%)
|
-106.63M
-140.28M – -73.62M
-41.7% YoY
|
-123.28M
-161.21M – -72.90M
-15.6% YoY
|
-143.53M
-162.82M – -68.90M
-16.4% YoY
|
-115.26M
-115.26M – -115.26M
+19.7% YoY
|
-102.59M
-102.59M – -102.59M
+11.0% YoY
|
| SGA |
13.27M
|
28.72M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.40
est: -5.26 (+73.4%)
|
-1.88
est: -2.00 (+5.8%)
|
-2.53
-3.51 – -1.84
-26.7% YoY
|
-2.78
-4.03 – -1.82
-10.0% YoY
|
-3.09
-4.07 – -1.72
-11.1% YoY
|
-2.88
-2.88 – -2.88
+6.7% YoY
|
-2.57
-2.57 – -2.57
+11.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-28 | Jones Trading | Buy | Buy | Maintain |
| 2026-04-27 | BTIG | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
39
Total invested
159.96M
Insider transactions (90d)
10
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
39
-61 vs prev Q
New positions
12
Closed positions
73
Increased
25
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 197.1K +197.1K (+100.0%) | 8.11B +8.1B (+100.0%) | 0.44% +0.443 pp | 8.02% +8.019 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.91M -540.3K (-5.2%) | 407.49M +100.3M (+32.6%) | 22.28% -1.400 pp | 4.17% +0.390 pp | USD10.46 +293.3% | 4 qtrs — |
| 3 | TPG GP A, LLC | 6.74M +— (+0.0%) | 277.49M +79.1M (+39.9%) | 15.17% -0.119 pp | 10.33% -0.475 pp | USD10.52 +291.1% | 4 qtrs — |
| 4 | ORBIMED ADVISORS LLC | 3.56M -143.3K (-3.9%) | 146.53M +37.6M (+34.5%) | 8.01% -0.388 pp | 3.00% +0.435 pp | USD10.46 +293.3% | 4 qtrs — |
| 5 | VIKING GLOBAL INVESTORS LP | 3.20M +— (+0.0%) | 131.45M +37.5M (+39.9%) | 7.19% -0.056 pp | 0.35% +0.105 pp | USD10.98 +274.7% | 4 qtrs — |
| 6 | ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 3.00M -619.9K (-17.1%) | 123.24M +16.9M (+15.9%) | 6.74% -1.458 pp | 14.24% +0.117 pp | USD10.46 +293.3% | 4 qtrs — |
| 7 | ENAVATE SCIENCES GP, LLC | 2.48M +— (+0.0%) | 101.95M +29.1M (+39.9%) | 5.57% -0.044 pp | 20.12% -2.135 pp | USD10.46 +293.3% | 4 qtrs — |
| 8 | BLACKROCK, INC. | 1.29M +447.0K (+52.9%) | 53.14M +28.3M (+113.9%) | 2.90% +0.990 pp | 0.00% +0.001 pp | USD26.46 +55.5% | 4 qtrs — |
| 9 | JPMORGAN CHASE & CO | 1.23M -746.8K (-37.7%) | 50.68M -7.5M (-12.9%) | 2.77% -1.715 pp | 0.00% 0.000 pp | USD10.62 +287.4% | 4 qtrs — |
| 10 | VANGUARD GROUP INC | 1.18M +41.8K (+3.7%) | 48.75M +15.1M (+45.0%) | 2.67% +0.074 pp | 0.00% +0.000 pp | USD20.23 +103.4% | 4 qtrs — |
| 11 | PERCEPTIVE ADVISORS LLC | 1.18M +— (+0.0%) | 48.51M +13.8M (+39.9%) | 2.65% -0.021 pp | 0.86% -0.137 pp | USD10.46 +293.3% | 4 qtrs — |
| 12 | JENNISON ASSOCIATES LLC | 1.12M +117.9K (+11.8%) | 45.88M +16.5M (+56.4%) | 2.51% +0.248 pp | 0.03% +0.011 pp | USD17.86 +130.3% | 4 qtrs — |
| 13 | CITADEL ADVISORS LLC | 1.09M +1.1M (+2,926.8%) | 44.73M +43.7M (+4,134.1%) | 2.45% +2.364 pp | 0.01% +0.007 pp | USD40.13 +2.5% | 4 qtrs — |
| 14 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 970.6K +— (+0.0%) | 39.93M +11.4M (+39.9%) | 2.18% -0.017 pp | 0.51% +0.074 pp | USD12.05 +241.4% | 4 qtrs — |
| 15 | ABRDN PLC | 840.0K -110.6K (-11.6%) | 34.56M +6.6M (+23.6%) | 1.89% -0.266 pp | 0.05% +0.009 pp | USD11.94 +244.6% | 4 qtrs — |
| 16 | PRICE T ROWE ASSOCIATES INC /MD/ | 831.4K +193.6K (+30.4%) | 34.20M +15.4M (+82.3%) | 1.87% +0.424 pp | 0.00% +0.002 pp | USD17.60 +133.8% | 4 qtrs — |
| 17 | STATE STREET CORP | 693.4K +453.2K (+188.7%) | 28.53M +21.5M (+303.8%) | 1.56% +1.015 pp | 0.00% +0.001 pp | USD34.77 +18.3% | 4 qtrs — |
| 18 | EVENTIDE ASSET MANAGEMENT, LLC | 639.0K +639.0K (+100.0%) | 26.29M +26.3M (+100.0%) | 1.44% +1.437 pp | 0.41% +0.411 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 19 | BAKER BROS. ADVISORS LP | 400.0K +— (+0.0%) | 16.46M +4.7M (+39.9%) | 0.90% -0.007 pp | 0.10% +0.011 pp | USD10.46 +293.3% | 4 qtrs — |
| 20 | GEODE CAPITAL MANAGEMENT, LLC | 380.0K +63.5K (+20.1%) | 15.64M +6.3M (+67.9%) | 0.85% +0.137 pp | 0.00% +0.000 pp | USD19.73 +108.5% | 4 qtrs — |
| 21 | SIREN, L.L.C. | 300.0K -25.0K (-7.7%) | 12.34M +2.8M (+29.1%) | 0.67% -0.062 pp | 0.37% -0.006 pp | USD10.46 +293.3% | 4 qtrs — |
| 22 | SOLEUS CAPITAL MANAGEMENT, L.P. | 268.5K -145.0K (-35.1%) | 11.05M -1.1M (-9.2%) | 0.60% -0.333 pp | 0.41% -0.205 pp | USD14.44 +184.9% | 4 qtrs — |
| 23 | SUPERSTRING CAPITAL MANAGEMENT LP | 180.6K +180.6K (+100.0%) | 7.43M +7.4M (+100.0%) | 0.41% +0.406 pp | 3.98% +3.978 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 24 | FRANKLIN RESOURCES INC | 175.5K -66.7K (-27.5%) | 7.22M +97.8K (+1.4%) | 0.39% -0.154 pp | 0.00% +0.000 pp | USD10.46 +293.3% | 4 qtrs — |
| 25 | ALYESKA INVESTMENT GROUP, L.P. | 136.2K -50.0K (-26.8%) | 5.60M +127.4K (+2.3%) | 0.31% -0.116 pp | 0.02% -0.001 pp | USD10.46 +293.3% | 4 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 123.7K +12.2K (+10.9%) | 5.09M +1.8M (+55.2%) | 0.28% +0.025 pp | 0.00% +0.000 pp | USD17.91 +129.7% | 4 qtrs — |
| 27 | ARTIA GLOBAL PARTNERS LP | 119.7K +119.7K (+100.0%) | 4.93M +4.9M (+100.0%) | 0.27% +0.269 pp | 0.79% +0.786 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 28 | TD ASSET MANAGEMENT INC | 113.4K +26.3K (+30.2%) | 4.66M +2.1M (+82.1%) | 0.25% +0.058 pp | 0.00% +0.002 pp | USD23.78 +73.0% | 4 qtrs — |
| 29 | NORTHERN TRUST CORP | 112.1K +14.4K (+14.7%) | 4.61M +1.7M (+60.5%) | 0.25% +0.031 pp | 0.00% +0.000 pp | USD19.38 +112.3% | 4 qtrs — |
| 30 | INVESCO LTD. | 111.2K +111.2K (+100.0%) | 4.57M +4.6M (+100.0%) | 0.25% +0.250 pp | 0.00% +0.001 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 31 | AMERIPRISE FINANCIAL INC | 101.6K -51.5K (-33.6%) | 4.18M -322.6K (-7.2%) | 0.23% -0.119 pp | 0.00% 0.000 pp | USD11.26 +265.4% | 4 qtrs — |
| 32 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 99.4K +— (+0.0%) | 4.09M +1.2M (+39.9%) | 0.22% -0.002 pp | 0.21% +0.039 pp | USD10.46 +293.3% | 4 qtrs — |
| 33 | UBS GROUP AG | 89.2K +42.5K (+91.1%) | 3.67M +2.3M (+167.3%) | 0.20% +0.095 pp | 0.00% +0.000 pp | USD27.91 +47.4% | 4 qtrs — |
| 34 | DRIEHAUS CAPITAL MANAGEMENT LLC | 83.9K +— (+0.0%) | 3.45M +983.6K (+39.9%) | 0.19% -0.002 pp | 0.02% +0.006 pp | USD10.46 +293.3% | 4 qtrs — |
| 35 | MILLENNIUM MANAGEMENT LLC | 80.5K -133.5K (-62.4%) | 3.31M -3.0M (-47.4%) | 0.18% -0.304 pp | 0.00% -0.001 pp | USD28.17 +46.0% | 4 qtrs — |
| 36 | ENSIGN PEAK ADVISORS, INC | 79.9K +79.9K (+100.0%) | 3.29M +3.3M (+100.0%) | 0.18% +0.180 pp | 0.01% +0.006 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 37 | LONGAEVA PARTNERS L.P. | 79.7K +18.3K (+29.7%) | 3.28M +1.5M (+81.5%) | 0.18% +0.040 pp | 0.28% +0.015 pp | USD32.10 +28.2% | 2 qtrs — |
| 38 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 69.4K +37.3K (+116.4%) | 2.87M +1.9M (+204.4%) | 0.16% +0.083 pp | 0.00% +0.002 pp | USD27.34 +50.5% | 4 qtrs — |
| 39 | SEVEN GRAND MANAGERS, LLC | 50.0K +50.0K (+100.0%) | 2.06M +2.1M (+100.0%) | 0.11% +0.113 pp | 0.16% +0.157 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 40 | MORGAN STANLEY | 49.9K +27.0K (+118.4%) | 2.05M +1.4M (+205.5%) | 0.11% +0.060 pp | 0.00% +0.000 pp | USD29.96 +37.3% | 4 qtrs — |
| 41 | BARCLAYS PLC | 48.2K +30.5K (+173.0%) | 1.98M +1.5M (+281.9%) | 0.11% +0.068 pp | 0.00% +0.000 pp | USD32.43 +26.9% | 3 qtrs — |
| 42 | BANK OF AMERICA CORP /DE/ | 43.6K +37.0K (+566.1%) | 1.79M +1.6M (+831.7%) | 0.10% +0.083 pp | 0.00% +0.000 pp | USD36.76 +11.9% | 4 qtrs — |
| 43 | SILVERARC CAPITAL MANAGEMENT, LLC | 41.5K -67.3K (-61.9%) | 1.71M -1.5M (-46.7%) | 0.09% -0.153 pp | 0.24% -0.195 pp | USD13.12 +213.6% | 4 qtrs — |
| 44 | WELLINGTON MANAGEMENT GROUP LLP | 38.3K -3.9K (-9.2%) | 1.58M +335.5K (+27.0%) | 0.09% -0.010 pp | 0.00% +0.000 pp | USD29.41 +39.9% | 2 qtrs — |
| 45 | ALPS ADVISORS INC | 36.6K +36.6K (+100.0%) | 1.51M +1.5M (+100.0%) | 0.08% +0.082 pp | 0.01% +0.009 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 46 | GOLDMAN SACHS GROUP INC | 36.3K +24.1K (+197.8%) | 1.49M +1.1M (+316.6%) | 0.08% +0.054 pp | 0.00% +0.000 pp | USD30.84 +33.4% | 4 qtrs — |
| 47 | BANK OF NEW YORK MELLON CORP | 35.1K +7.7K (+27.9%) | 1.45M +637.7K (+79.0%) | 0.08% +0.017 pp | 0.00% +0.000 pp | USD23.69 +73.7% | 3 qtrs — |
| 48 | POLEN CAPITAL MANAGEMENT LLC | 31.3K +— (+0.0%) | 1.29M +366.7K (+39.9%) | 0.07% -0.001 pp | 0.01% +0.003 pp | USD22.86 +80.0% | 3 qtrs — |
| 49 | RAFFERTY ASSET MANAGEMENT, LLC | 24.7K +24.7K (+100.0%) | 1.02M +1.0M (+100.0%) | 0.06% +0.056 pp | 0.00% +0.004 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 50 | NUVEEN, LLC | 23.7K +7.7K (+48.0%) | 976.4K +504.7K (+107.0%) | 0.05% +0.017 pp | 0.00% +0.000 pp | USD25.06 +64.2% | 3 qtrs — |
| 51 | RUSSELL INVESTMENTS GROUP, LTD. | 21.9K +20.9K (+2,046.9%) | 902.7K +872.6K (+2,903.3%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD40.59 +1.4% | 2 qtrs — |
| 52 | RHUMBLINE ADVISERS | 17.7K +454.0 (+2.6%) | 727.9K +220.9K (+43.6%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD17.96 +129.1% | 3 qtrs — |
| 53 | WELLS FARGO & COMPANY/MN | 17.6K +10.0K (+131.7%) | 722.0K +499.2K (+224.1%) | 0.04% +0.022 pp | 0.00% +0.000 pp | USD31.70 +29.8% | 3 qtrs — |
| 54 | SQUAREPOINT OPS LLC | 16.4K +6.2K (+61.0%) | 673.1K +374.2K (+125.2%) | 0.04% +0.014 pp | 0.00% +0.000 pp | USD33.85 +21.5% | 4 qtrs — |
| 55 | ALLIANCEBERNSTEIN L.P. | 15.6K +15.6K (+100.0%) | 642.6K +642.6K (+100.0%) | 0.04% +0.035 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 56 | SG AMERICAS SECURITIES, LLC | 10.7K +10.7K (+100.0%) | 440.0K +440.0K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 57 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 10.3K +5.3K (+105.4%) | 422.6K +275.5K (+187.4%) | 0.02% +0.012 pp | 0.03% +0.020 pp | USD35.43 +16.1% | 2 qtrs — |
| 58 | DEUTSCHE BANK AG\ | 10.0K +433.0 (+4.5%) | 412.6K +130.4K (+46.2%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD18.38 +123.8% | 3 qtrs — |
| 59 | PROFUND ADVISORS LLC | 9.2K +9.2K (+100.0%) | 379.0K +379.0K (+100.0%) | 0.02% +0.021 pp | 0.01% +0.012 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 60 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 8.9K +3.3K (+58.0%) | 367.1K +201.2K (+121.2%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD26.08 +57.7% | 3 qtrs — |
| 61 | METLIFE INVESTMENT MANAGEMENT, LLC | 8.6K +532.0 (+6.6%) | 352.4K +116.1K (+49.1%) | 0.02% +0.001 pp | 0.00% +0.001 pp | USD18.83 +118.5% | 3 qtrs — |
| 62 | INTECH INVESTMENT MANAGEMENT LLC | 7.6K +103.0 (+1.4%) | 312.2K +92.0K (+41.8%) | 0.02% +0.000 pp | 0.00% +0.001 pp | USD29.57 +39.1% | 2 qtrs — |
| 63 | KENNEDY CAPITAL MANAGEMENT LLC | 6.8K +6.8K (+100.0%) | 277.8K +277.8K (+100.0%) | 0.02% +0.015 pp | 0.01% +0.006 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 64 | TWO SIGMA INVESTMENTS, LP | 6.4K +6.4K (+100.0%) | 263.3K +263.3K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 65 | VIRTUS INVESTMENT ADVISERS, INC. | 6.2K -478.0 (-7.1%) | 255.9K +58.9K (+29.9%) | 0.01% -0.001 pp | 0.07% +0.013 pp | USD19.44 +111.6% | 3 qtrs — |
| 66 | AMERICAN CENTURY COMPANIES INC | 6.2K +6.2K (+100.0%) | 254.2K +254.2K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 67 | DARK FOREST CAPITAL MANAGEMENT LP | 6.0K +6.0K (+100.0%) | 246.5K +246.5K (+100.0%) | 0.01% +0.014 pp | 0.01% +0.011 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 68 | D. E. SHAW & CO., INC. | 5.7K +5.7K (+100.0%) | 236.2K +236.2K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 69 | NEW YORK STATE COMMON RETIREMENT FUND | 5.3K +— (+0.0%) | 218.0K +62.2K (+39.9%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD17.35 +137.1% | 3 qtrs — |
| 70 | CITIGROUP INC | 5.2K +4.5K (+654.7%) | 213.3K +193.1K (+955.7%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD37.99 +8.3% | 3 qtrs — |
| 71 | XTX TOPCO LTD | 4.9K +4.9K (+100.0%) | 202.7K +202.7K (+100.0%) | 0.01% +0.011 pp | 0.01% +0.005 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 72 | PROSHARE ADVISORS LLC | 4.9K +4.9K (+100.0%) | 201.7K +201.7K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 73 | LOS ANGELES CAPITAL MANAGEMENT LLC | 5.2K +5.2K (+100.0%) | 197.2K +197.2K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.001 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 74 | CIBC PRIVATE WEALTH GROUP, LLC | 4.5K +4.5K (+100.0%) | 185.1K +185.1K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 75 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 4.2K +998.0 (+30.9%) | 174.1K +79.0K (+83.1%) | 0.01% +0.002 pp | 0.00% +0.001 pp | USD24.74 +66.3% | 3 qtrs — |
| 76 | ALPHACENTRIC ADVISORS LLC | 2.7K +2.7K (+100.0%) | 111.9K +111.9K (+100.0%) | 0.01% +0.006 pp | 0.11% +0.112 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 77 | BNP PARIBAS ARBITRAGE, SNC | 2.3K -116.0 (-4.9%) | 93.1K +23.1K (+33.1%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD20.49 +100.8% | 3 qtrs — |
| 78 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.2K +2.2K (+100.0%) | 89.2K +89.2K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 79 | LEGAL & GENERAL GROUP PLC | 1.7K -5.7K (-77.2%) | 69.2K -148.0K (-68.1%) | 0.00% -0.013 pp | 0.00% +0.000 pp | USD27.16 +51.5% | 3 qtrs — |
| 80 | BALYASNY ASSET MANAGEMENT L.P. | 1.4K +1.4K (+100.0%) | 57.8K +57.8K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 81 | AMERITAS INVESTMENT PARTNERS, INC. | 1.3K +43.0 (+3.4%) | 53.6K +16.5K (+44.7%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD18.14 +126.8% | 3 qtrs — |
| 82 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.1K -3.4K (-74.9%) | 46.4K -85.6K (-64.8%) | 0.00% -0.008 pp | 0.00% -0.003 pp | USD29.41 +39.9% | 2 qtrs — |
| 83 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 988.00 +217.0 (+28.1%) | 40.6K +18.0K (+79.3%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD22.59 +82.1% | 3 qtrs — |
| 84 | GF FUND MANAGEMENT CO. LTD. | 876.00 +876.0 (+100.0%) | 36.0K +36.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.001 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 85 | ROYAL BANK OF CANADA | 489.00 +111.0 (+29.4%) | 21.0K +10.0K (+90.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD29.74 +38.3% | 4 qtrs — |
| 86 | AMALGAMATED BANK | 504.00 +83.0 (+19.7%) | 21.0K +9.0K (+75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD21.27 +93.4% | 3 qtrs — |
| 87 | FMR LLC | 384.00 +150.0 (+64.1%) | 15.8K +8.9K (+129.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD33.99 +21.0% | 2 qtrs — |
| 88 | FARTHER FINANCE ADVISORS, LLC | 190.00 +190.0 (+100.0%) | 7.8K +7.8K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD41.14 +0.0% | 1 qtrs NEW |
| 89 | GAMMA INVESTING LLC | 177.00 +24.0 (+15.7%) | 7.3K +2.8K (+61.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD30.99 +32.8% | 2 qtrs — |
| 90 | DAIWA SECURITIES GROUP INC. | 149.00 +149.0 (+100.0%) | 6.0K +6.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD41.13 +0.0% | 1 qtrs NEW |
| 91 | STERLING CAPITAL MANAGEMENT LLC | 105.00 +75.0 (+250.0%) | 4.3K +3.4K (+389.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD34.33 +19.8% | 3 qtrs — |
| 92 | CWM, LLC | 80.00 +20.0 (+33.3%) | 3.0K +1.0K (+50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD32.33 +27.3% | 2 qtrs — |
| 93 | US BANCORP \DE\ | 65.00 -46.0 (-41.4%) | 2.7K -591.0 (-18.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD29.40 +39.9% | 2 qtrs — |
| 94 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 48.00 +48.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD41.13 +0.0% | 1 qtrs NEW |
| 95 | ASTER CAPITAL MANAGEMENT (DIFC) LTD | 37.00 -372.0 (-91.0%) | 1.5K -10.5K (-87.3%) | 0.00% -0.001 pp | 0.00% -0.005 pp | USD29.41 +39.9% | 4 qtrs — |
| 96 | ALLWORTH FINANCIAL LP | 28.00 +6.0 (+27.3%) | 1.2K +504.0 (+77.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD31.89 +29.0% | 2 qtrs — |
| 97 | HUGHES FINANCIAL SERVICES, LLC | 25.00 -19.0 (-43.2%) | 1.0K -545.0 (-34.6%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD17.32 +137.5% | 3 qtrs — |
| 98 | EVERSOURCE WEALTH ADVISORS, LLC | 20.00 +— (+0.0%) | 823.00 +235.0 (+40.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD29.40 +39.9% | 2 qtrs — |
| 99 | PNC FINANCIAL SERVICES GROUP, INC. | 5.00 +— (+0.0%) | 206.00 +59.0 (+40.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD29.40 +39.9% | 2 qtrs — |
| 100 | ROTHSCHILD INVESTMENT LLC | 1.00 +1.0 (+100.0%) | 41.00 +41.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD41.00 +0.3% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 77 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 1.04% | 2.22M | 0.50% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.78% | 446.7K | 0.65% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.27% | 97.9K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.27% | 29.41M | 0.35% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.14% | 104.4K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.14% | 1.56M | 0.35% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.14% | 650.7K | 0.40% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.14% | 105.0K | 0.19% |
| 9 | Vanguard U.S. Momentum Factor ETF VFMO | 0.14% | 2.32M | 0.13% |
| 10 | iShares Biotechnology ETF IBB | 0.09% | 8.57M | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
16
Shares acquired
—
Shares disposed
1.72M
Cash buys
—
Cash sales
16.00
Net activity
-1,717,760
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 184,639 | 46.22 | 8.53M | 2,671,822 | I | ↗ |
| 2026-05-11 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 184,639 | 46.22 | 8.53M | 2,671,822 | I | ↗ |
| 2026-05-08 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 59,767 | 44.58 | 2.66M | 2,856,461 | I | ↗ |
| 2026-05-08 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 59,767 | 44.58 | 2.66M | 2,856,461 | I | ↗ |
| 2026-05-07 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 48,546 | 44.61 | 2.17M | 2,916,228 | I | ↗ |
| 2026-05-07 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 48,546 | 44.61 | 2.17M | 2,916,228 | I | ↗ |
| 2026-04-18 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 2,948 | 44.52 | 131.2K | 2,964,774 | I | ↗ |
| 2026-04-18 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 2,948 | 44.52 | 131.2K | 2,964,774 | I | ↗ |
| 2026-04-17 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 52,397 | 44.68 | 2.34M | 2,967,722 | I | ↗ |
| 2026-04-17 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 52,397 | 44.68 | 2.34M | 2,967,722 | I | ↗ |
| 2026-04-16 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 226,906 | 45.34 | 10.29M | 3,020,119 | I | ↗ |
| 2026-04-16 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 226,906 | 45.34 | 10.29M | 3,020,119 | I | ↗ |
| 2026-04-15 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 235,863 | 44.64 | 10.53M | 3,247,025 | I | ↗ |
| 2026-04-15 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 235,863 | 44.64 | 10.53M | 3,247,025 | I | ↗ |
| 2026-04-14 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 47,814 | 44.51 | 2.13M | 3,482,888 | I | ↗ |
| 2026-04-14 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 47,814 | 44.51 | 2.13M | 3,482,888 | I | ↗ |
| 2026-03-05 | Fitzpatrick Jennifer | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 10,250 | 6.11 | 62.6K | 50,935 | D | ↗ |
| 2026-02-03 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 29,063 | 44.58 | 1.30M | 3,530,702 | I | ↗ |
| 2026-02-03 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 29,063 | 44.58 | 1.30M | 3,530,702 | I | ↗ |
| 2026-02-02 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 1,890 | 44.57 | 84.2K | 3,559,765 | I | ↗ |
| 2026-02-02 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 1,890 | 44.57 | 84.2K | 3,559,765 | I | ↗ |
| 2026-01-22 | TPG GP A, LLC | 10% Owner | S-Sale | D | Common Stock | 250,000 | 40.00 | 10.00M | 6,494,962 | I | ↗ |
| 2026-01-02 | Ridloff Elena | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 165,440 | 39.21 | 6.49M | 165,440 | D | ↗ |
| 2026-01-02 | McKee Charlotte | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 155,700 | 39.21 | 6.10M | 155,700 | D | ↗ |
| 2026-01-02 | Fitzpatrick Jennifer | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 103,140 | 39.21 | 4.04M | 103,140 | D | ↗ |
| 2026-01-02 | Cloonan Michael | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 436,100 | 39.21 | 17.10M | 436,100 | D | ↗ |
| 2026-01-02 | Beer Caroline Stark | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 139,340 | 39.21 | 5.46M | 139,340 | D | ↗ |
| 2025-12-24 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 33,356 | 44.55 | 1.49M | 3,561,655 | I | ↗ |
| 2025-12-24 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 33,356 | 44.55 | 1.49M | 3,561,655 | I | ↗ |
| 2025-12-19 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 875 | 44.49 | 38.9K | 3,595,011 | I | ↗ |
| 2025-12-19 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 875 | 44.49 | 38.9K | 3,595,011 | I | ↗ |
| 2025-12-18 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 100 | 44.49 | 4.4K | 3,595,886 | I | ↗ |
| 2025-12-18 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 100 | 44.49 | 4.4K | 3,595,886 | I | ↗ |
| 2025-12-17 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 900 | 44.50 | 40.1K | 3,595,986 | I | ↗ |
| 2025-12-17 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 900 | 44.50 | 40.1K | 3,595,986 | I | ↗ |
| 2025-12-05 | Fitzpatrick Jennifer | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 10,250 | 6.11 | 62.6K | 61,185 | D | ↗ |
| 2025-11-26 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 1,600 | 44.49 | 71.2K | 3,596,886 | I | ↗ |
| 2025-11-26 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 1,600 | 44.49 | 71.2K | 3,596,886 | I | ↗ |
| 2025-11-25 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 11,890 | 44.60 | 530.3K | 3,598,486 | I | ↗ |
| 2025-11-25 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 11,890 | 44.60 | 530.3K | 3,598,486 | I | ↗ |
| 2025-11-24 | Thompson Peter A. | Director | S-Sale | D | Common Stock | 94,583 | 44.54 | 4.21M | 3,610,376 | I | ↗ |
| 2025-11-24 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 94,583 | 44.54 | 4.21M | 3,610,376 | I | ↗ |
| 2025-11-21 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 7,609 | 39.50 | 300.6K | 159,033 | I | ↗ |
| 2025-11-20 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 801 | 39.89 | 32.0K | 2,205,034 | I | ↗ |
| 2025-11-19 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 18,684 | 40.01 | 747.5K | 662,266 | I | ↗ |
| 2025-11-18 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 2,092 | 39.57 | 82.8K | 182,527 | I | ↗ |
| 2025-11-17 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 280 | 42.10 | 11.8K | 2,219,739 | I | ↗ |
| 2025-10-28 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 31,392 | 39.58 | 1.24M | 715,988 | I | ↗ |
| 2025-10-24 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 107,941 | 39.50 | 4.26M | 219,867 | I | ↗ |
| 2025-10-21 | Cloonan Michael | Director / Officer | S-Sale | D | Common Stock | 33,532 | 37.31 | 1.25M | 547,343 | D | ↗ |
| 2025-10-21 | Booth Bruce | Director | S-Sale | D | Common Stock | 25,327 | 35.69 | 903.9K | 2,309,118 | I | ↗ |
| 2025-10-20 | Booth Bruce | Director | S-Sale | D | Common Stock | 4,300 | 31.79 | 136.7K | 707,397 | I | ↗ |
| 2025-10-17 | Booth Bruce | Director | S-Sale | D | Common Stock | 248 | 33.47 | 8.3K | 2,428,768 | I | ↗ |
| 2025-10-16 | Cloonan Michael | Director / Officer | S-Sale | D | Common Stock | 200 | 34.00 | 6.8K | 547,343 | D | ↗ |
| 2025-10-16 | Booth Bruce | Director | S-Sale | D | Common Stock | 15,384 | 32.84 | 505.2K | 725,006 | I | ↗ |
| 2025-10-15 | Cloonan Michael | Director / Officer | S-Sale | D | Common Stock | 14,775 | 31.11 | 459.7K | 547,343 | D | ↗ |
| 2025-10-15 | Booth Bruce | Director | S-Sale | D | Common Stock | 6,303 | 31.12 | 196.1K | 751,664 | I | ↗ |
| 2025-10-14 | Booth Bruce | Director | S-Sale | D | Common Stock | 105 | 29.95 | 3.1K | 771,762 | I | ↗ |
| 2025-10-13 | Booth Bruce | Director | S-Sale | D | Common Stock | 44,048 | 30.32 | 1.34M | 2,719,526 | I | ↗ |
| 2025-10-10 | Booth Bruce | Director | S-Sale | D | Common Stock | 3,511 | 29.98 | 105.3K | 781,969 | I | ↗ |
| 2025-10-06 | Booth Bruce | Director | S-Sale | D | Common Stock | 9,753 | 29.95 | 292.1K | 2,780,301 | I | ↗ |
| 2025-10-03 | Booth Bruce | Director | S-Sale | D | Common Stock | 31,198 | 30.00 | 935.9K | 2,790,054 | I | ↗ |
| 2025-10-01 | Booth Bruce | Director | S-Sale | D | Common Stock | 165 | 29.95 | 4.9K | 2,821,252 | I | ↗ |
| 2025-10-01 | Beer Caroline Stark | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 255,000 | 28.47 | 7.26M | 255,000 | D | ↗ |
| 2025-09-30 | Booth Bruce | Director | S-Sale | D | Common Stock | 2,149 | 30.06 | 64.6K | 794,110 | I | ↗ |
| 2025-09-29 | Cloonan Michael | Director / Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 7,793 | 6.11 | 47.6K | 178,142 | D | ↗ |
| 2025-09-29 | Booth Bruce | Director | S-Sale | D | Common Stock | 11,468 | 30.09 | 345.1K | 796,259 | I | ↗ |
| 2025-09-26 | Cloonan Michael | Director / Officer | M-Exempt | A | Common Stock | 17,207 | 6.11 | 105.1K | 564,550 | D | ↗ |
| 2025-09-04 | Fitzpatrick Jennifer | Officer | M-Exempt | A | Common Stock | 10,250 | 6.11 | 62.6K | 10,250 | D | ↗ |
| 2025-09-02 | Ridloff Elena | Officer | S-Sale | D | Common Stock | 8,836 | 25.08 | 221.6K | 38,532 | D | ↗ |
| 2025-08-29 | Ridloff Elena | Officer | S-Sale | D | Common Stock | 748 | 25.18 | 18.8K | 47,368 | D | ↗ |
| 2025-08-28 | Ridloff Elena | Officer | S-Sale | D | Common Stock | 16,098 | 25.97 | 418.1K | 48,116 | D | ↗ |
| 2025-08-27 | Ridloff Elena | Officer | S-Sale | D | Common Stock | 3,618 | 25.10 | 90.8K | 64,214 | D | ↗ |
| 2025-08-27 | Cloonan Michael | Director / Officer | M-Exempt | A | Common Stock | 7,426 | 6.11 | 45.4K | 554,769 | D | ↗ |
| 2025-08-26 | Ridloff Elena | Officer | S-Sale | D | Common Stock | 3,700 | 25.13 | 93.0K | 67,832 | D | ↗ |
| 2025-08-26 | Cloonan Michael | Director / Officer | M-Exempt | A | Common Stock | 17,574 | 6.11 | 107.4K | 564,917 | D | ↗ |
| 2025-08-20 | Ridloff Elena | Officer | S-Sale | D | Common Stock | 17,500 | 22.69 | 397.1K | 71,532 | D | ↗ |
| 2025-08-20 | Cloonan Michael | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 6.11 | 152.8K | 572,343 | D | ↗ |
| 2025-08-19 | Ridloff Elena | Officer | S-Sale | D | Common Stock | 34,500 | 21.08 | 727.3K | 89,032 | D | ↗ |
| 2025-06-27 | TPG GP A, LLC | 10% Owner | P-Purchase | A | Common Stock | 60,000 | 15.84 | 950.4K | 6,744,962 | I | ↗ |
| 2025-06-12 | Viney Joanne L. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
| 2025-06-12 | Thompson Peter A. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
| 2025-06-12 | Stelzer Laurie | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
| 2025-06-12 | Ruddy Marcella K. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
| 2025-06-12 | Resnick Joshua | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
| 2025-06-12 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | I | ↗ |
| 2025-06-12 | Fleming Harold Edward | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
| 2025-06-12 | Clancy Paul J | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
| 2025-06-12 | Booth Bruce | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 19,959 | 16.99 | 339.1K | 19,959 | D | ↗ |
Executive team
Top executives
Shares Outstanding
45.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael Cloonan, M.B.A. President and Chief Executive Officer | 646.6K | — | — | 5.95M | 374.1K | 10.0K | 6.98M | 85.24% | ↗ |
| 2 | 2025 | Caroline Stark Beer, M.B.A. Chief Business Officer | 158.9K | 30.0K | — | 5.32M | 71.6K | 7.6K | 5.59M | 95.21% | ↗ |
| 3 | 2025 | Elena Ridloff, C.F.A. Chief Financial Officer | 506.7K | — | — | 2.09M | 254.9K | 10.0K | 2.86M | 73.00% | ↗ |
| 4 | 2024 | Michael Cloonan, M.B.A. President and Chief Executive Officer | 506.2K | — | — | 2.94M | 278.4K | — | 3.73M | 78.95% | ↗ |
| 5 | 2024 | Elena Ridloff, C.F.A. Chief Financial Officer | 449.9K | — | — | 652.7K | 198.0K | — | 1.30M | 50.18% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Cloonan | President, Chief Executive Officer & Director | 1M | male |
| Elena H. Ridloff | Chief Financial Officer | 771.6K | female |
| Charlotte McKee | Chief Medical Officer | 647.9K | — |
| Caroline Stark Beer | Chief Business Officer | 268.1K | female |
| Mara Furlow | Senior Vice President of Global Regulatory Affairs & Quality | — | female |
| Mark Munson | Co-founder & Senior Vice President of Medicinal Chemistry | — | — |
| Meghan Bagshaw | Vice President of Programs, Portfolio & Operations | — | female |
| Andy Chu | Vice President of Information & Technology | — | male |
| Vanya Sagar | Chief People Officer | — | female |
| Greg Hurlbut | Co-Founder & Senior Vice President of Discovery Research | — | — |
| Jennifer Fitzpatrick | Chief Legal Officer | — | female |
| Kenneth A. Lock | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SION
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
